Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
NetherlandsIPO:
26 March 2021Website:
http://www.lavatherapeutics.comNext earnings report:
22 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 49 min agoDividend
Analysts recommendations
Institutional Ownership
LVTX Latest News
UTRECHT, The Netherlands and PHILADELPHIA, June 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics, will present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference.
UTRECHT, The Netherlands and PHILADELPHIA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will participate in a virtual fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference which will be available on Monday, September 11, 2023 at 7:00 am ET.
LAVA Therapeutics N.V. (LVTX) came out with a quarterly loss of $0.48 per share in line with the Zacks Consensus Estimate.
Lava (LVTX) falls 10% due to its decision to discontinue the study on LAVA-051, which is being evaluated for multiple hematological tumors. The company shifts focus to LAVA-1207 in the prostate cancer study.
What type of business is LAVA Therapeutics NV?
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
What sector is LAVA Therapeutics NV in?
LAVA Therapeutics NV is in the Healthcare sector
What industry is LAVA Therapeutics NV in?
LAVA Therapeutics NV is in the Biotechnology industry
What country is LAVA Therapeutics NV from?
LAVA Therapeutics NV is headquartered in Netherlands
When did LAVA Therapeutics NV go public?
LAVA Therapeutics NV initial public offering (IPO) was on 26 March 2021
What is LAVA Therapeutics NV website?
https://www.lavatherapeutics.com
Is LAVA Therapeutics NV in the S&P 500?
No, LAVA Therapeutics NV is not included in the S&P 500 index
Is LAVA Therapeutics NV in the NASDAQ 100?
No, LAVA Therapeutics NV is not included in the NASDAQ 100 index
Is LAVA Therapeutics NV in the Dow Jones?
No, LAVA Therapeutics NV is not included in the Dow Jones index
When does LAVA Therapeutics NV report earnings?
The next expected earnings date for LAVA Therapeutics NV is 22 August 2024